Baker Bros. Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Baker Bros. Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-609,166	Closed	-$8.82M	–	119
2017 Q4	$8.82M	Hold	609,166	–	–	0.08%	61
2017 Q3	$9.61M	Hold	609,166	–	–	0.08%	53
2017 Q2	$7.57M	Hold	609,166	–	–	0.07%	54
2017 Q1	$9.9M	Hold	609,166	–	–	0.08%	50
2016 Q4	$9.19M	Hold	609,166	–	–	0.09%	51
2016 Q3	$9.28M	Hold	609,166	–	–	0.08%	58
2016 Q2	$23.6M	Hold	609,166	–	–	0.25%	29
2016 Q1	$16.9M	Hold	609,166	–	–	0.18%	39
2015 Q4	$32.8M	Hold	609,166	–	–	0.27%	32
2015 Q3	$24.4M	Buy	609,166 +505,000	+485%	+$16.5M	0.23%	34
2015 Q2	$3.33M	Hold	104,166	–	–	0.03%	89
2015 Q1	$2.49M	Buy	+104,166	New	+$2.33M	0.02%	99

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baker Bros. Advisors's ITCI Position: Q1 2018 in Review

Baker Bros. Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2018, closing a stake of 609,166 shares — an estimated $8.82M sold.

Baker Bros. Advisors first reported a position in ITCI in Q1 2015 and held it in 12 quarters. The position peaked at $32.8M in Q4 2015. 131 funds tracked by Wall St. Rank hold ITCI as of Q1 2018.

Baker Bros. Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2018 after selling out during the quarter.
Baker Bros. Advisors sold 609,166 Intra-Cellular Therapies Inc. shares in Q1 2018, an estimated $8.82M.
Baker Bros. Advisors first reported a position in Intra-Cellular Therapies Inc. in Q1 2015 and held it in 12 quarters.
Baker Bros. Advisors's Intra-Cellular Therapies Inc. position peaked at $32.8M in Q4 2015.
131 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2018.

Based on Baker Bros. Advisors's 13F filing for Q1 2018, filed 15 May 2018.